NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER

CompletedN/A

Sponsor: AstraZeneca

Conditions: Urothelial Carcinoma, Non Muscle Invasive Bladder Cancer, Muscle-invasive Bladder Cancer

Countries: Brazil

A national, multicenter, non-randomized, retrospective, observational study (Real-World Evidence-RWE) aimed at analyzing clinical presentation profiles and demographic characteristics of patients with early urothelial bladder cancer (high-risk non-muscle invasive and localized muscle-invasive) treated with standard therapies in national cancer treatment reference centers within the last 6 years (between 2017 and 2022).

Eligibility overview

Sex: ALL

Age: 18 Years to 100 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Age ≥ 18 years old;
* Diagnosis of high-risk non-muscle invasive urothelial carcinoma, defined as:
* T1 tumor and/or high-grade lesion (G3) and/or presence of CIS.
* Multifocal relapsed tumor and with at least one large lesion (diameter ≥ 3 cm);
* Diagnosis of early muscle-invasive urothelial bladder carcinoma (cT2, cT3 or cT4a N0);
* Consent to participate in the study.

Exclusion Criteria:

* Low-risk non-muscle invasive urothelial carcinoma (single lesion, pTa and low-grade);
* Locally advanced muscle-invasive urothelial carcinoma (suspected lymph node impairment in staging imaging tests) or metastatic at diagnosis;
* Bladder carcinoma with non-urothelial histology (adenocarcinoma, squamous-cell carcinoma or small cell carcinoma);

Locations (5)

Belo Horizonte, Brazil
Porto Alegre, Brazil
Recife, Brazil
Salvador, Brazil
São Paulo, Brazil